Nasopharyngeal cancer
ICD-10 C11 · ICD-11 2B6B

Treatment of Newly Diagnosed Metastatic Nasopharyngeal Carcinoma

This protocol addresses patients presenting with newly diagnosed metastatic nasopharyngeal carcinoma — disease that is distant at the time of first diagnosis, before any systemic therapy has been given.

Clinical Approach

Management in this setting combines palliative systemic chemotherapy as the first-line backbone with the selective addition of locoregional radiotherapy targeting involved sites — an approach supported by evidence showing improvement in locoregional control and overall survival.

Full regimen details, drug selection, sequencing, and eligibility criteria are available in the complete structured protocol below.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2020.12.007

  • A treatment combination of cisplatin and gemcitabine is the first-line choice and improves OS [I, A].
  • In patients with newly diagnosed metastatic NPC, the addition of locoregional RT to systemic therapy improves locoregional control and ultimately OS [II, A].
View source ↗